RU2020121222A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2020121222A3 RU2020121222A3 RU2020121222A RU2020121222A RU2020121222A3 RU 2020121222 A3 RU2020121222 A3 RU 2020121222A3 RU 2020121222 A RU2020121222 A RU 2020121222A RU 2020121222 A RU2020121222 A RU 2020121222A RU 2020121222 A3 RU2020121222 A3 RU 2020121222A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593084P | 2017-11-30 | 2017-11-30 | |
| US62/593,084 | 2017-11-30 | ||
| PCT/IB2018/059383 WO2019106550A1 (en) | 2017-11-30 | 2018-11-28 | Fxr agonists for the treatment of liver diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020121222A RU2020121222A (ru) | 2021-12-30 |
| RU2020121222A3 true RU2020121222A3 (cg-RX-API-DMAC7.html) | 2022-04-19 |
Family
ID=64959384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020121222A RU2020121222A (ru) | 2017-11-30 | 2018-11-28 | Агонисты fxr для лечения заболеваний печени |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210361638A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3716977A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021504370A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200094175A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111356458A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018376904B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3081656A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL274747A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020005557A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2020121222A (cg-RX-API-DMAC7.html) |
| TW (1) | TW201936189A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019106550A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021014349A1 (en) * | 2019-07-23 | 2021-01-28 | Novartis Ag | Treatment comprising fxr agonists |
| CN114502198A (zh) * | 2019-09-30 | 2022-05-13 | 诺华股份有限公司 | 包括使用fxr激动剂的治疗 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005089316A2 (en) * | 2004-03-12 | 2005-09-29 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using fxr ligands |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| LT3419625T (lt) | 2016-02-22 | 2021-07-26 | Novartis Ag | Fxr agonistų panaudojimo būdai |
| HK1257648A1 (zh) * | 2016-02-22 | 2019-10-25 | Novartis Ag | Fxr促效剂之使用方法 |
| SI3419624T1 (sl) * | 2016-02-22 | 2021-05-31 | Novartis Ag | Postopki za uporabo agonistov FXR |
| AR114930A1 (es) * | 2017-09-12 | 2020-11-11 | Novartis Ag | Composición farmacéutica |
-
2018
- 2018-11-28 CN CN201880074342.4A patent/CN111356458A/zh active Pending
- 2018-11-28 KR KR1020207017973A patent/KR20200094175A/ko not_active Ceased
- 2018-11-28 EP EP18830302.8A patent/EP3716977A1/en not_active Withdrawn
- 2018-11-28 TW TW107142391A patent/TW201936189A/zh unknown
- 2018-11-28 MX MX2020005557A patent/MX2020005557A/es unknown
- 2018-11-28 US US16/767,078 patent/US20210361638A1/en not_active Abandoned
- 2018-11-28 JP JP2020528867A patent/JP2021504370A/ja active Pending
- 2018-11-28 AU AU2018376904A patent/AU2018376904B2/en not_active Ceased
- 2018-11-28 CA CA3081656A patent/CA3081656A1/en active Pending
- 2018-11-28 RU RU2020121222A patent/RU2020121222A/ru unknown
- 2018-11-28 US US16/202,637 patent/US20190161483A1/en not_active Abandoned
- 2018-11-28 WO PCT/IB2018/059383 patent/WO2019106550A1/en not_active Ceased
-
2020
- 2020-05-18 IL IL274747A patent/IL274747A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL274747A (en) | 2020-07-30 |
| CA3081656A1 (en) | 2019-06-06 |
| EP3716977A1 (en) | 2020-10-07 |
| US20190161483A1 (en) | 2019-05-30 |
| AU2018376904B2 (en) | 2021-07-22 |
| KR20200094175A (ko) | 2020-08-06 |
| US20210361638A1 (en) | 2021-11-25 |
| TW201936189A (zh) | 2019-09-16 |
| CN111356458A (zh) | 2020-06-30 |
| RU2020121222A (ru) | 2021-12-30 |
| MX2020005557A (es) | 2020-08-20 |
| AU2018376904A1 (en) | 2020-05-21 |
| WO2019106550A1 (en) | 2019-06-06 |
| JP2021504370A (ja) | 2021-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR122021000189A2 (cg-RX-API-DMAC7.html) | ||
| BR112019008823A2 (cg-RX-API-DMAC7.html) | ||
| BR112019025875B1 (pt) | Sistema de cilindro com estrutura de ocupação de movimento relativo | |
| BR112020011860B1 (pt) | Dispositivo cirúrgico para cortar uma lente dentro de um saco capsular de um olho | |
| BR112020006283B1 (pt) | Placa refinadora, e, refinador para tratamento mecânico de material orgânico/celulósico | |
| BR112020009729B1 (pt) | Inibidores de acss2 e métodos de uso dos mesmos | |
| BR112020008714B1 (pt) | Uso de medicamentos serotoninérgicos para tratar trombocitopenia induzida por vírus | |
| BR112020006992B1 (pt) | Dispositivo de recolhimento e método para o recolhimento de uma embarcação | |
| BR112019023976B1 (pt) | Sistema e método para comunicar dados de saúde em um ambiente de cuidados de saúde | |
| BR112020003314B1 (pt) | Sistema terapêutico transdérmico para administração transdérmica de um agente ativo, seu método de fabricação, usos de emulsificante, e método para estabilizar uma mistura de revestimento bifásica | |
| BR112020003112B1 (pt) | Método de garantir a viabilidade de uma máquina para uma tarefa agendada | |
| BR112020002577B1 (pt) | Método de melhoria de rendimento de centrifugação dupla para purificação de óleo nutritivo | |
| BR112019016885B1 (pt) | Remodelagem de imagem integrada e codificação de vídeo | |
| BR112019027876B1 (pt) | Método de codificação para uma comunicação sem fio, codificador, método de decodificação, decodificador, aparelho de comunicação, meio de armazenagem legível por computador, e sistema de comunicações | |
| BR112020001354B1 (pt) | Método, em uma primeira estação base, para suportar posicionamento de um dispositivo móvel e primeira estação base para suportar posicionamento de um dispositivo móvel | |
| BR112019026818B1 (pt) | Método de codificação, método de decodificação, aparelho, aparelho de comunicações, terminal, estação base e mídia legível por computador | |
| BR112019026880B1 (pt) | Método de comunicação, método para receber dados, e, dispositivo | |
| BR102018011961B1 (pt) | Sistemas, métodos e meio não transitório legível por computador para analisar cores a partir de uma plataforma de mídia social | |
| BR112019023944B1 (pt) | Combinação farmacêutica para o tratamento de um câncer | |
| BR112019021396B1 (pt) | Processo para fabricação de pululano | |
| BR102018003507B1 (pt) | Sistema de isolamento de tensão de tambor de guincho | |
| BR112019016182B1 (pt) | Método para diagnosticar risco de revisão relacionado a implante | |
| BR112019014127B1 (pt) | Composição farmacêutica para tratamento de tumores | |
| BR112019017156B1 (pt) | Dispositivo, sistema e método de gerenciamento de recepção de pedido, e, meio de armazenamento legível por computador | |
| BR102017026429B1 (pt) | Método de extração subsequente de ácidos graxos e dna genômico a partir de dípteros |